New treatment could reduce brain damage from stroke, study in mice shows

As many as one in four people will have a stroke during their lifetime. This is when a blood clot prevents oxygen from reaching a part of the brain. The first few hours following a stroke are crucial – the blood clot needs to be removed quickly so that the oxygen supply to the brain can be restored; otherwise, the brain tissue begins to die.
Currently, the outcome for stroke patients receiving even the best available treatment, known as mechanical thrombectomy, is still poor, with fewer than one in 10 patients leaving hospital with no neurological impairment.
Professor Thomas Krieg from the Department of Medicine at the University of Cambridge said: “Stroke is a devastating disease. Even for those who survive, there is a significant risk of damage to the brain that can lead to disabilities and a huge impact on an individual’s life. But in terms of treatment, once the stroke is happening, we have only limited options.”
Mechanical thrombectomy is a minimally invasive medical procedure involving the insertion of a thin tube, known as a catheter, into a blood vessel, often through the groin or arm. This is guided to the blood clot, where it is removed by a tiny device, restoring normal blood flow.
Restoring blood flow too suddenly can make things worse, however. This is called ischaemia-reperfusion injury. When blood rushes back into the oxygen-starved tissue (a process known as reperfusion), the damaged cells struggle to cope, leading to the production of harmful molecules called free radicals that can damage cells, proteins, and DNA. This triggers further damage and can cause an inflammatory response.
The Cambridge team has previously shown that when the brain is starved of oxygen, a build-up occurs of a chemical called succinate. When blood flow is restored, the succinate is rapidly oxidised to drive free radical production within mitochondria, the ‘batteries’ that power our cells, initiating the extra damage. This occurs within the first few minutes of reperfusion, but the researchers showed that the oxidation of succinate can be blocked by the molecule malonate.
Professor Mike Murphy from the Medical Research Council Mitochondrial Biology Unit said: “All of this happens very rapidly, but if we can get malonate in quickly at the start of reperfusion, we can prevent this oxidation and burst of free radicals.
“We discovered in our labs that we can get malonate into cells very quickly by lowering the pH a little, making it a bit more acidic, so that it can cross the blood-brain barrier better. If we inject it into the brain just as we’re ready to reperfuse, then we can potentially prevent further damage.”
In a study published in Cardiovascular Research, the team has shown that treating the brain with a form of the chemical known as acidified disodium malonate (aDSM) alongside mechanical thrombectomy greatly decreased the amount of brain damage that occurs from ischaemia-reperfusion injury by as much as 60%.
Dr Jordan Lee, a postdoctoral researcher in the group, developed a mouse model that mimics mechanical thrombectomy, allowing the team to test the effectiveness of aDSM against ischaemia-reperfusion injury.
Dr Lee said: “This approach reduces the amount of dead brain tissue resulting from a stroke. This is incredibly important because the amount of dead brain tissue is directly correlated to the patient’s recovery – to their disability, whether they can still use all their limbs, speak and understand language, for example.”
Mechanical thrombectomy is increasingly used in the NHS, and the researchers hope that with the addition of aDSM as a treatment alongside this intervention, they will be able to improve outcomes significantly when the procedure is more widely adopted.
The team has launched Camoxis Therapeutics, a spin-out company, with support from Cambridge Enterprise, the innovation arm of the University of Cambridge. It is now seeking seed funding to develop the drug further and take it to early-stage clinical trials.
Professor Murphy added: “If it’s successful, this same drug could have much wider applications for other instances of ischemia-reperfusion injuries, such as heart attack, resuscitation, organ transplantation, and so on, which have similar underlying mechanisms.”
The research was supported by the British Heart Foundation, Medical Research Council, Wellcome Trust and the National Institute for Health and Care Research Cambridge Biomedical Research Centre.
Reference
Lee, JJ et al. Local arterial administration of acidified malonate as an adjunct therapy to mechanical thrombectomy in ischemic stroke. Cardiovascular Research; 27 Jun 2025; DOI: 10.1093/cvr/cvaf118
Cambridge scientists have developed and tested a new drug in mice that has the potential to reduce damage to the brain when blood flow is restored following a stroke.
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.